Literature DB >> 3377460

Pharmacokinetics of cefonicid in patients with skin and skin structure infections.

K L Heim-Duthoy1, G L Peltier, D R Guay, G R Matzke.   

Abstract

The disposition of cefonicid (2 g intravenously every 24 h) was assessed in 15 patients with skin and skin structure infections. Trough and peak concentrations in serum were measured on two successive days to verify the attainment of steady state; and 1 trough and 12 postdose values of the concentration in serum were collected on the following day. Cefonicid concentrations in serum were determined by high-performance liquid chromatography. The cefonicid serum concentration versus time profile after intravenous infusion was clearly biexponential in all patients. The terminal elimination half-life determined by nonlinear regression analysis was 4.63 +/- 1.49 h (mean +/- standard deviation). The steady-state volume of distribution and total body clearance were 0.12 +/- 0.04 liter/kg and 0.369 +/- 0.110 ml/min per kg, respectively. These results are comparable to parameters derived from previous studies in noninfected normal volunteers. Thus, the disposition of cefonicid is not altered in patients with severe skin and skin structure infections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3377460      PMCID: PMC172206          DOI: 10.1128/AAC.32.4.485

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

Review 2.  Pharmacokinetic changes in aging.

Authors:  J L Cohen
Journal:  Am J Med       Date:  1986-05-16       Impact factor: 4.965

3.  Computation of model-independent pharmacokinetic parameters during multiple dosing.

Authors:  L A Bauer; M Gibaldi
Journal:  J Pharm Sci       Date:  1983-08       Impact factor: 3.534

4.  Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin.

Authors:  S L Barriere; G J Hatheway; J G Gambertoglio; E T Lin; J E Conte
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

5.  Pharmacokinetics of ceftazidime and netilmicin in patients with sepsis.

Authors:  U Ganzinger; G Kleinberger; K Lenz; F Schatz; A Laggner; G Grimm
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1987-07

Review 6.  Review of cefonicid, a long-acting cephalosporin.

Authors:  M N Dudley; R Quintiliani; C H Nightingale
Journal:  Clin Pharm       Date:  1984 Jan-Feb

7.  Multiple-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects.

Authors:  E A Swabb; A A Sugerman; D N McKinstry
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

8.  Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis.

Authors:  S L Barriere; J G Gambertoglio; D P Alexander; R J Stagg; J E Conte
Journal:  Rev Infect Dis       Date:  1984 Nov-Dec

Review 9.  Drug prescribing in renal failure: dosing guidelines for adults.

Authors:  W M Bennett; G R Aronoff; G Morrison; T A Golper; J Pulliam; M Wolfson; I Singer
Journal:  Am J Kidney Dis       Date:  1983-11       Impact factor: 8.860

10.  Pharmacokinetics of aztreonam in patients with gram-negative infections.

Authors:  D M Janicke; R F Cafarell; S W Parker; M A Apicella; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

View more
  1 in total

1.  Pharmacokinetics of cefepime in patients with respiratory tract infections.

Authors:  J M Kovarik; J C ter Maaten; C M Rademaker; M Deenstra; I M Hoepelman; H C Hart; G R Matzke; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.